Oak Family Advisors LLC Sells 94,271 Shares of Sanofi (NASDAQ:SNY)

Oak Family Advisors LLC cut its holdings in Sanofi (NASDAQ:SNY - Free Report) by 60.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 60,621 shares of the company's stock after selling 94,271 shares during the period. Sanofi accounts for about 1.3% of Oak Family Advisors LLC's holdings, making the stock its 29th biggest position. Oak Family Advisors LLC's holdings in Sanofi were worth $3,015,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in SNY. Rise Advisors LLC increased its position in Sanofi by 98.4% during the fourth quarter. Rise Advisors LLC now owns 506 shares of the company's stock worth $25,000 after purchasing an additional 251 shares during the last quarter. SRS Capital Advisors Inc. boosted its holdings in Sanofi by 289.1% in the first quarter. SRS Capital Advisors Inc. now owns 463 shares of the company's stock valued at $25,000 after acquiring an additional 344 shares during the last quarter. Householder Group Estate & Retirement Specialist LLC purchased a new stake in Sanofi during the third quarter valued at about $26,000. Fairfield Bush & CO. acquired a new stake in Sanofi during the first quarter worth about $26,000. Finally, Indiana Trust & Investment Management CO purchased a new position in shares of Sanofi in the 3rd quarter worth about $27,000. Hedge funds and other institutional investors own 10.04% of the company's stock.

Sanofi Stock Up 0.7 %

SNY stock traded up $0.31 during trading on Monday, reaching $46.24. The stock had a trading volume of 1,997,215 shares, compared to its average volume of 1,845,782. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The firm has a fifty day moving average price of $47.60 and a 200 day moving average price of $48.81. The company has a market capitalization of $116.97 billion, a P/E ratio of 19.46, a PEG ratio of 1.72 and a beta of 0.61. Sanofi has a 1-year low of $42.63 and a 1-year high of $57.82.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). The business had revenue of $11.76 billion during the quarter, compared to analyst estimates of $13.02 billion. Sanofi had a return on equity of 27.47% and a net margin of 12.56%. On average, equities analysts anticipate that Sanofi will post 4.16 earnings per share for the current year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be given a $1.478 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a dividend yield of 2.98%. This is an increase from Sanofi's previous annual dividend of $1.38. Sanofi's payout ratio is presently 58.47%.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Morgan Stanley initiated coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They set an "equal weight" rating and a $55.00 target price for the company. TheStreet cut shares of Sanofi from a "b" rating to a "c" rating in a research report on Friday, February 9th. Finally, StockNews.com lowered Sanofi from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $55.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.